The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial

• Main Authors: Jianwei Liao (Author), Liyun Yang (Author), Luping Zhou (Author), Hongbin Zhao (Author), Xiao Qi (Author), Yimin Cui (Author), Dongsheng Ouyang (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Hyzetimibe is a novel inhibitor of cholesterol that specifically targets the NPC1L1 gene. Significant inter-individual variability suggests the existence of an abundance of poor responders and non-responders. In addition, the current literature is inconsistent and controversial regarding...